ONESOURCE (Onesource Specialty Pharma Ltd.): Partnership / JV
Onesource Specialty Pharma has informed the exchange that it has entered into a strategic manufacturing partnership with Formycon AG for biosimilars, according to an NSE filing dated 14 July.
Partnership and joint-venture announcements have historically produced mixed outcomes. Across 68 comparable events in Strota's database, such announcements have recorded a 51.5% win rate with a net edge of 0.22%, meaning events like this have historically shown a slight positive skew in short-term returns but with nearly even odds of outperformance versus underperformance.
The stock closed at ₹1,673 on 13 July, trading 19.88% below its 52-week high of ₹2,088 and 58.28% above its 52-week low of ₹1,057. Relative volume stands at 2.72, indicating elevated trading activity. The 14-day RSI reads 53.2, a neutral reading. The stock sits above its 200-day simple moving average but below its 50-day. The company carries a market capitalisation of ₹19,305 crore, trades at a price-to-book ratio of 3.32, and reported negative earnings per share of ₹6.51 with a return on equity of -1.3%.
The filing confirms the partnership arrangement but does not disclose financial terms, revenue commitments, or timeline milestones. The data establishes that the announcement coincides with above-average volume and a neutral technical setup, but does not establish whether the partnership will translate into measurable revenue or margin improvement.
The catalyst
Onesource Specialty Pharma Limited has informed the Exchange regarding 'OneSource Specialty Pharma and Formycon AG announceStrategic Manufacturing Partnership for Biosimilars'. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Partnership / JV shows no reliable next-session edge — the move went bullish in about 51.5% of next sessions (net 0.22% after drift and cost, n=68). A base rate, not a forecast for this stock.
ONESOURCE right now
trading +0.57% on the day; RSI 53.2. Full ONESOURCE analysis →
Sources
- Onesource Specialty Pharma Limited has informed the Exchange regarding 'OneSource Specialty Pharma and Formycon AG announceStrategic Manufacturing Partnership for Biosimilars'. — NSE
- Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key client — CNBC TV18
- ONESOURCE SPECIALTY PHARMA LTD. Share Price Today Down 5% — Equitymaster
- OneSource Specialty Pharma shares fall as Q4 profit plunges 95%, margin halves — CNBC TV18
- JSW Holdings Ltd leads losers in 'A' group — Business Standard
Keep digging
- ONESOURCE — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.